ArticlePloS one2015
TOX acts an oncological role in mycosis fungoides.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Retraction: QKI5mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis.Oncotarget · 2026Article
- The Tox Gene Encodes Two Proteins with Distinct and Shared Roles in Gene Regulation.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.Turk patoloji dergisi · 2023Article
- Article
- TOX Expression in Mycosis Fungoides and Sezary Syndrome.Diagnostics (Basel, Switzerland) · 2022Article
- Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides.Diagnostics (Basel, Switzerland) · 2022Article
- Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4Cancers · 2021Article
- Diagnosis of Early Mycosis Fungoides.Diagnostics (Basel, Switzerland) · 2021Review
- NLRP3 Regulates IL-4 Expression in TOXFrontiers in immunology · 2021Article
- Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.Archives of dermatological research · 2020Article
- Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies.Cancers · 2020Review
- Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Review
- TOX expression and role in CTCL.Journal of the European Academy of Dermatology and Venereology : JEADV · 2016Article
- TOX expression in cutaneous B-cell lymphomas.Archives of dermatological research · 2016Article
- Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.Current hematologic malignancy reports · 2015Review
Corrections and comments
- Retraction · 2023-05-04Concerns/Issues about Authorship/Affiliation · Duplication of/in Article · Compromised Peer Review · Paper Mill ·
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycosis fungoides (MF) is a low-grade lymphoma characterized by clonal expansion of atypical CD4+ skin-homing T lymphocytes. Herein, we examined the role of thymocytes selection associated HMG-box (TOX), a gene previously found to be unregulated in MF skin biopsies, in MF pathogenesis. TOX encodes a high-mobility group family (HMG) domain DNA binding nuclear protein, which regulates the differentiation of developing T-cells. First, we confirmed that TOX expression levels in MF were increased compared with those in benign inflammatory dermatitis (BID) and normal skin. In addition, TOX level increased with the progression MF from patch stage to tumor stage. Overexpression of TOX accelerated the proliferation and migration of MF cell lines in vitro, which were blocked by AKT inhibitors. In conclusion, our study confirmed that TOX was highly expressed in MF lesions and accelerates the proliferation and migration of MF. TOX is a diagnostic marker for MF and may play a pathogenic role in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.